Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

New Haven bioscience incubator opens

“We feel we’re going to lead the way,” said John Geibel, speaking at the ribbon-cutting for the New Haven Innovation Labs, a new startup space...

| By Kelley Gipson

Quantum-Si acquires Majelac Technologies

Quantum-Si, a Guilford-based protein sequencing company, has acquired Majelac Technologies LLC. The privately-owned Majelac, which is based in Pennsylvania, provides semiconductor packaging and integrated circuit...

| By Kelley Gipson

ReNetX completes enrollment in spinal cord study

ReNetX Bio has reported successful completion of patient enrollment in Part 2 of its RESET study. The RESET study (Part 2) is a multiple dose, double-blind, placebo-controlled...

| By Kelley Gipson

Stamford’s Cara names Christopher Posner new CEO

Stamford’s Cara Therapeutics has named Christopher Posner president and CEO, effective November 9. Posner succeeds Derek Chalmers, who will transition to a senior adviser role. Chalmers co-founded the...

| By Kelley Gipson

UConn professor studies trichomes in cannabis

Cannabis has been gaining more and more attention as a promising tool for the medical community. Yet much of the plant’s biology remains a mystery...

| By Kelley Gipson

Pfizer/Biohaven deal to market migraine drug

Pharma giant Pfizer is betting on Biohaven Pharmaceuticals and its migraine drug Nurtec ODT, also known as rimegepant, agreeing to pay $500 million upfront for the rights to commercialize...

| By Kelley Gipson

IsoPlexis leverages new tech to fight diseases

It has been a time of growth for Yale life sciences spinout IsoPlexis. CEO Sean Mackay co-founded the company with Rong Fan, a professor of biomedical...